Given the complexity of the IGF-1R/IR family and the dynamic predominance of specific receptors and ligands in individual tumors, each class of anti-IGF/IGF-1R agents may offer unique advantages and different toxicity profiles in selected tumor settings [164]. The gene discussed is IGF1R; the disease is neoplasm.